Skip to main content
. 2021 Aug 1;12(5):1168–1178. doi: 10.1002/jcsm.12754

Figure 3.

Figure 3

Prevalence and relative risk of significant liver fibrosis according to the status of metabolic dysfunction‐associated fatty liver disease (MAFLD)/sarcopenia. The prevalence and relative risk of significant liver fibrosis [(A) by fibrosis‐4 index (FIB‐4) and (B) by non‐alcoholic fatty liver disease fibrosis score (NFS)] significantly increased from non‐sarcopenic subjects with MAFLD to sarcopenic subjects with MAFLD, compared with those without MAFLD (all P < 0.001). CI, confidence interval; OR, odds ratio.